Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Tumor necrosis factor-alpha at the intersection of mycobacterial immunity and pathogenesis: an important new address in medicine.

Iseman MD, Fischer A.

Clin Infect Dis. 2008 Jun 1;46(11):1741-2. doi: 10.1086/587990. No abstract available.

2.

Dominant-negative tumor necrosis factor protects from Mycobacterium bovis Bacillus Calmette Guérin (BCG) and endotoxin-induced liver injury without compromising host immunity to BCG and Mycobacterium tuberculosis.

Olleros ML, Vesin D, Lambou AF, Janssens JP, Ryffel B, Rose S, Frémond C, Quesniaux VF, Szymkowski DE, Garcia I.

J Infect Dis. 2009 Apr 1;199(7):1053-63. doi: 10.1086/597204.

3.

Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network.

Winthrop KL, Yamashita S, Beekmann SE, Polgreen PM; Infectious Diseases Society of America Emerging Infections Network.

Clin Infect Dis. 2008 Jun 1;46(11):1738-40. doi: 10.1086/587989.

4.

Mycobacterium tuberculosis 38-kDa lipoprotein is apoptogenic for human monocyte-derived macrophages.

Sanchez A, Espinosa P, Esparza MA, Colon M, Bernal G, Mancilla R.

Scand J Immunol. 2009 Jan;69(1):20-8. doi: 10.1111/j.1365-3083.2008.02193.x.

PMID:
19140873
5.

Antitumour necrosis factor-alpha treatment, statins, regulatory T cells and tuberculosis.

Goldstein MR, Mascitelli L, Pezzetta F.

Aliment Pharmacol Ther. 2008 Apr 1;27(7):619. doi: 10.1111/j.1365-2036.2008.03614.x. Epub 2008 Jan 14. No abstract available.

6.

The interaction of monocyte chemoattractant protein-1 and tumour necrosis factor-alpha in Mycobacterium tuberculosis-induced HIV-1 replication at sites of active tuberculosis.

Mayanja-Kizza H, Wu M, Aung H, Liu S, Luzze H, Hirsch C, Toossi Z.

Scand J Immunol. 2009 Jun;69(6):516-20. doi: 10.1111/j.1365-3083.2009.02246.x.

PMID:
19439012
7.

Illuminating the black box of TNF action in tuberculous granulomas.

Miller EA, Ernst JD.

Immunity. 2008 Aug 15;29(2):175-7. doi: 10.1016/j.immuni.2008.07.003.

8.

Development of leprosy in a patient with ankylosing spondylitis during the infliximab treatment: reactivation of a latent infection?

Vilela Lopes R, Barros Ohashi C, Helena Cavaleiro L, de Britto Pereira Cruz R, da Veiga RR, Fernando Ribeiro Miranda M, Toshimitsu Yoshikawa G.

Clin Rheumatol. 2009 May;28(5):615-7. doi: 10.1007/s10067-009-1140-0. Epub 2009 Mar 4.

PMID:
19259757
9.

Latent infection and tuberculosis disease in rheumatoid arthritis patients.

Acevedo-Vásquez E, Ponce de León D, Gamboa-Cárdenas R.

Rheum Dis Clin North Am. 2009 Feb;35(1):163-81. doi: 10.1016/j.rdc.2009.03.008. Review.

PMID:
19481003
10.

Mycobacterium tuberculosis infection of human monocyte-derived macrophages leads to apoptosis of T cells.

Sharma S, Sharma M, Bose M.

Immunol Cell Biol. 2009 Mar-Apr;87(3):226-34. doi: 10.1038/icb.2008.97. Epub 2008 Dec 23.

PMID:
19104503
11.

Mycobacterial interaction with innate receptors: TLRs, C-type lectins, and NLRs.

Jo EK.

Curr Opin Infect Dis. 2008 Jun;21(3):279-86. doi: 10.1097/QCO.0b013e3282f88b5d. Review.

PMID:
18448973
12.

Mycobacterial disease in patients with rheumatic disease.

van Ingen J, Boeree MJ, Dekhuijzen PN, van Soolingen D.

Nat Clin Pract Rheumatol. 2008 Dec;4(12):649-56. doi: 10.1038/ncprheum0949. Review.

PMID:
19037226
13.

Cyclic AMP intoxication of macrophages by a Mycobacterium tuberculosis adenylate cyclase.

Agarwal N, Lamichhane G, Gupta R, Nolan S, Bishai WR.

Nature. 2009 Jul 2;460(7251):98-102. doi: 10.1038/nature08123. Epub 2009 Jun 10.

PMID:
19516256
14.

Usual suspects: anti-TNF drugs.

Onat AM.

Clin Rheumatol. 2010 Apr;29(4):447-8. doi: 10.1007/s10067-009-1356-z. Epub 2010 Jan 22. No abstract available.

PMID:
20094745
15.

The Koch phenomenon and the immunopathology of tuberculosis.

Rook GA, Stanford JL.

Curr Top Microbiol Immunol. 1996;215:239-62. Review. No abstract available.

PMID:
8791717
16.

T-cell responses against tuberculin and sensitin in children with tuberculosis and non-tuberculosis mycobacterial lymphadenopathy.

Magdorf K, Schuck SD, Leitner S, Wahn U, Kaufmann SH, Jacobsen M.

Clin Microbiol Infect. 2008 Nov;14(11):1079-83. doi: 10.1111/j.1469-0691.2008.02084.x.

17.

Mycobacterium bovis bacillus Calmette-Guérin infection induces TLR2-dependent peroxisome proliferator-activated receptor gamma expression and activation: functions in inflammation, lipid metabolism, and pathogenesis.

Almeida PE, Silva AR, Maya-Monteiro CM, Töröcsik D, D'Avila H, Dezsö B, Magalhães KG, Castro-Faria-Neto HC, Nagy L, Bozza PT.

J Immunol. 2009 Jul 15;183(2):1337-45. doi: 10.4049/jimmunol.0900365. Epub 2009 Jun 26.

18.

Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans.

Bruns H, Meinken C, Schauenberg P, Härter G, Kern P, Modlin RL, Antoni C, Stenger S.

J Clin Invest. 2009 May;119(5):1167-77. doi: 10.1172/JCI38482. Epub 2009 Apr 20.

19.

Making tumor necrosis factor blockers safer: a prescriber's consumptive challenge.

Keane J, Ní Cheallaigh C.

J Rheumatol. 2008 Jul;35(7):1238-9. Epub 2008 Jun 15. No abstract available.

20.

Neutrophil extracellular traps are induced by Mycobacterium tuberculosis.

Ramos-Kichik V, Mondragón-Flores R, Mondragón-Castelán M, Gonzalez-Pozos S, Muñiz-Hernandez S, Rojas-Espinosa O, Chacón-Salinas R, Estrada-Parra S, Estrada-García I.

Tuberculosis (Edinb). 2009 Jan;89(1):29-37. doi: 10.1016/j.tube.2008.09.009. Epub 2008 Dec 3.

PMID:
19056316
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk